Introduction
============

A type II clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 system of *Streptococcus pyogenes*, derived from the bacterial adaptive immune system has been developed into convenient genome engineering tools for diverse organisms, such as *Escherichia coli* ([@B19]), *Streptomyces* spp. ([@B9]), *Saccharomyces cerevisiae* ([@B10]), mice ([@B34]), *Bomyx mori* ([@B38]), Drosophila ([@B3]), crop plants ([@B33]), and human cell lines ([@B25]). The CRISPR/Cas9 system requires the CRISPR-associated protein (Cas9), a trans-activating CRISPR RNA (tracrRNA), and a CRISPR RNA (crRNA). A synthetic single guide RNA (sgRNA) is constructed by fusing together the tracrRNA and the crRNA. The endonuclease Cas9 and sgRNA, including a 20 bp target sequence, which is decided by protospacer adjacent motif (PAM), are enough to make a double-strand DNA break (DSB) in a specific region of the genome ([@B20]; [@B2]). The DSB can be repaired using two mechanisms---the homology directed repair (HDR) and the non-homologous end joining (NHEJ). For the HDR pathway, donor DNA fragment that is homologous to the region flanking DSB site is required to repair the cleavage site. The NHEJ system repairs the broken end without the donor DNA and results in the insertion or deletion (indel) mutations. The CRISPR/Cas9 systems can provide an efficient tool for editing the genome ([@B11]).

Several types of CRISPR/Cas9-based genome editing system have been reported in *B. subtilis*, including chromosome-integrated method, single-, or two-plasmid systems ([@B15]). The chromosome-integrated CRISPR/Cas9 was used for single or double gene mutation, and for the insertion of a 2.9 kb hyaluronic acid biosynthetic operon. However, this method has a limitation -- the gRNA integration site must be restored to its original form in order to introduce a new gRNA cassette ([@B40]). A single-plasmid-based method was used for the disruption of multiple genes, which are *srfC*, *spoIIAC*, *nprE*, *aprE*, and *amyE*, with an efficiency of 33--53% ([@B43]). In addition, a two-plasmid CRISPR/Cas9 system was introduced for *spo0A* deletion, *sigE* point mutation, *gfp* gene insertion, and large-sized gene deletion in *B. subtilis* ([@B36]). The two-plasmid system showed the highest mutation efficiency. However, the plasmid-based gene editing systems still require an iterative process of removing the plasmid containing the previous sgRNA, and for introducing the plasmid carrying a new sgRNA for the multi-round genome editing. The previous methods for plasmid removal were usually dependent on a temperature sensitive replication origin or a traditional negative selection method, which are labor-intensive and time-consuming ([@B37]). Therefore, a method that can remove the specific plasmid DNA with high efficiency would facilitate multi-round genome editing.

In *E. coli*, CRISPR/Cas9-mediated plasmid curing methods have used replicon, or antibiotic resistant marker-targeting sgRNAs for plasmid recycling ([@B19]; [@B23]; [@B32]; [@B21]). These systems have used inducible promoters for the controlled transcription of the sgRNAs in order to avoid the transcription of the self-targeting sgRNA (sgRNA~st~), prior to chromosome-targeting sgRNA (sgRNA~ct~). However, the CRISPR/Cas9-mediated plasmid curing has not yet been reported in *B. subtilis*. Several inducible promoters have been used in the *B. subtilis*, such as P~spac~ and P~xyl~. However, they have substantial basal expression levels despite the absence of an inducer ([@B4]). Using a sporulation-specific promoter for tightly controlled transcription of the sgRNA~st~, we have developed here a CRISPR/Cas9-based multi-round genome editing system in which the genome editing and automatic plasmid curing occur in sequence during cultivation. The system was used to construct a *B. subtilis* mutant, containing eight extracellular proteases' deletion without the remainder of any foreign DNA trace.

Materials and Methods {#s1}
=====================

Strains and Culture Conditions
------------------------------

The plasmids and *B. subtilis* strains used in this study are listed in [Table 1](#T1){ref-type="table"}. *E. coli* MC1061 was used to construct the recombinant plasmids. *B. subtilis* cells were cultured in Luria-Bertani (LB), LB agar (Difco Laboratories, Detroit, MI, United States) and 2×GYS (2 g/L glucose, 4 g/L (NH~4~)~2~SO~4~, 4 g/L yeast extract, 1 g/L K~2~HPO~4~, 0.82 g/L MgSO~4~⋅7H~2~O, 0.16 g/L CaCl~2~⋅2H~2~O, and 0.14 g/L MnSO~4~⋅5H~2~O, pH 7.0) for sporulation at 37°C. To test the efficiency of the plasmid cleavage, 100 mM IPTG (Isopropyl β-D-1-thiogalactopyranoside) was added to the 2×GYS (final concentration of 1 mM), named 2×GYS-I. When required, the antibiotics were supplemented with ampicillin (100 μg/ml), neomycin (10 μg /ml) or chloramphenicol (5 μg /ml). Transformation of *B. subtilis* was carried out utilizing the two-step transformation procedure ([@B13]) except that the EGTA (ethylene glycol-bis(2-aminoethyl ether) N, N, N′, N′-tetraacetic acid) was not used.

###### 

*Bacillus* strains and plasmids used in this study.

  Strain/plasmid           Genotype/description                                                                                                                              References
  ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------
  ***BACILLUS* STRAINS**                                                                                                                                                     
  *B. subtilis* 168        Tryptophan auxotrophic (trpC2)                                                                                                                    Laboratory stock
  BS-C100                  *B. subtilis* 168 containing plasmid pHCas9                                                                                                       [@B36]
  BS-D119a                 BS-C100 containing plasmid pSC1                                                                                                                   This study
  BS-D119b                 BS-C100 Δ*aprE* containing plasmid pG2-aE                                                                                                         This study
  BS-D119c                 BS-C100 Δ*aprE* containing plasmid pG-aE                                                                                                          This study
  BS-D119                  BS-C100 Δ*aprE*                                                                                                                                   This study
  BS-D120                  BS-C100 Δ*aprE* Δ*nprE*                                                                                                                           This study
  BS-D121                  BS-C100 Δ*aprE* Δ*nprE* Δ*epr*                                                                                                                    This study
  BS-D122                  BS-C100 Δ*aprE* Δ*nprE* Δ*epr* Δ*bpr*                                                                                                             This study
  BS-D123                  BS-C100 Δ*aprE* Δ*nprE* Δ*epr* Δ*bpr* Δ*mpr*                                                                                                      This study
  BS-D124                  BS-C100 Δ*aprE* Δ*nprE* Δ*epr* Δ*bpr* Δ*mpr* Δ*nprB*                                                                                              This study
  BS-D125                  BS-C100 Δ*aprE* Δ*nprE* Δ*epr*Δ*bpr* Δ*mpr* Δ*nprB* Δ*vpr*                                                                                        This study
  BS-D126                  BS-C100 Δ*aprE*Δ*nprE*Δ*epr* Δ*bpr* Δ*mpr* Δ*nprB* Δ*vpr* Δ*wprA*                                                                                 This study
  **PLASMIDS**                                                                                                                                                               
  pAD123                   *E. coli*-*Bacillus* shuttle vector                                                                                                               Bacillus Genetic Stock Center
  pAgR                     Plasmid pAD123 derivative containing synthetic sgRNA module                                                                                       [@B36]
  pSC1                     Plasmid pAD123 derivative containing sgRNA module with 20 bp self-targeting gRNA under the control of sporulation-specific promoter P~spoIV\ A~   This study
  pG2                      Plasmid pSC1 containing synthetic sgRNA module under the control of the constitute promoter (Para)                                                This study
  pG2-aE                   Plasmid pG2 containing *aprE*-targeting 20 bp gRNA and 1 kb Donor DNA                                                                             This study
  pG-aE                    Plasmid pG2-aE without sporulation-specific promoter P~spoIV\ A~ and 20 bp self-targeting gRNA                                                    This study
  pG2-nE                   Plasmid pG2 containing *nprE*-targeting 20 bp gRNA and 1 kb Donor DNA                                                                             This study
  pG2-er                   Plasmid pG2 containing *epr*-targeting 20 bp gRNA and 1 kb Donor DNA                                                                              This study
  pG2-br                   Plasmid pG2 containing *bpr*-targeting 20 bp gRNA and 1 kb Donor DNA                                                                              This study
  pG2-mr                   Plasmid pG2 containing *mpr*-targeting 20 bp gRNA and 1 kb Donor DNA                                                                              This study
  pG2-nB                   Plasmid pG2 containing *nprB*-targeting 20 bp gRNA and 1 kb Donor DNA                                                                             This study
  pG2-vr                   Plasmid pG2 containing *vpr*-targeting 20 bp gRNA and 1 kb Donor DNA                                                                              This study
  pG2-wA                   Plasmid pG2 containing *wprA*-targeting 20 bp gRNA and 1 kb Donor DNA                                                                             This study

Plasmids Construction
---------------------

The primers used in this study are listed in [Table 2](#T2){ref-type="table"}. The sporulation-specific promoter (P~spoIV\ A~) and sgRNA~st~, containing 20 bp of self-targeting sequences, was obtained through a fusion polymerase chain reaction (PCR) with primers spoIVA-rep-F1 and spoIVA-rep-R1. The PCR product was digested with EcoRI and BamHI and inserted into corresponding sites of plasmid pAD123 ([@B17]) to construct the pSC1. To introduce the synthetic sgRNA module under the control of the constitute promoter (P~ara~) into the plasmid pSC1, primers g-AarI-F1 and g-AarI-R1 were used to amplify the promoter and the synthetic sgRNA module, using the pAgR ([@B36]) as a template. The PCR product was digested with BglII and NsiI and ligated with large a fragment of BamHI- and NsiI-digested pSC1, to construct plasmid pG2.

###### 

Oligonucleotides and Primers used in this study.

  Oligonucleotide   Sequence (5′→3′)
  ----------------- ------------------------------------------------------------------------------------------------------------
  aprE-gF1          Attg**accgattgagttattaagag**
  aprE-gR1          Aaac**ctcttaataactcaatcggt**
  nprE-gF1          Attg**agacaagcgtgcccggaagg**
  nprE-gR1          Aaac**ccttccgggcacgcttgtct**
  epr-gF1           Attg**ttaaaccagtattatgcaac**
  epr-gR1           Aaac**gttgcataatactggtttaa**
  bpr-gF1           Attg**ataacggaaagacatcaagc**
  bpr-gR1           Aaac**gcttgatgtctttccgttat**
  mpr-gF1           Attg**tatccgtacggtacttattc**
  mpr-gR1           Aaac**gaataagtaccgtacggata**
  nprB-gF1          Attg**tctcaactgatcgggtatac**
  nprB-gR1          Aaac**gtatacccgatcagttgaga**
  vpr-gF1           Attg**aaagtcgccgttgtcaaacg**
  vpr-gR1           Aaac**cgtttgacaacggcgacttt**
  wprA-gF1          Attg**atattcagtacccttatcaa**
  wprA-gR1          Aaac**ttgataagggtactgaatat**
                    
  **Primer**        **Sequence (5′→3′)**
                    
  spoIVA-rep-F1     Caa[gaattc]{.ul}gatgtcatattcaaataggacaacgtcatacacatatagtgca aatttctgcgatgatggagttttagagctagaaatagcaagttaaa
  spoIVA-rep-R1     Aga[ggatcc]{.ul}aaaaaaagcaccgactcggtgccactttttcaagttgataac ggactagccttattttaacttgctatttctagctctaaaactccat
  g-AarI-F1         Ta[agatctaagctt]{.ul}aaagattgacagtataatagtc
  g-AarI-R1         Aaa[atgcatactagt]{.ul}a[gctag]{.ul}ca[ggatcc]{.ul}aaaaaaagcaccgactc
  aprE-NF1          T[ggatcc]{.ul}tagttatttcgagtctctacgg
  aprE-NR1          tgtgcaatatgatcttcttcc
  aprE-CF1          Ggaagaagatcatattgcacatcggctaccctgcaaaatat
  aprE-CR1          At[actagt]{.ul}cggtgcttgtgaagattttca
  nprE-NF1          T[ggatcc]{.ul}ttatcaatcagcctgccaggt
  nprE-NR1          Taagcaagacgatagctgcc
  nprE-CF1          Ggcagctatcgtcttgcttatgatggcgacggttcattctt
  nprE-CR1          At[actagt]{.ul}cttcaactttagcggcatca
  epr-NF1           Gcagaccaggagacagtaaaa
  epr-NR1           Tcgtgccaaggctcatattga
  epr-CF1           Tcaatatgagccttggcacgatgccgaactccgacgccaaaa
  epr-CR1           At[actagt]{.ul}tcttcactttgtctaaccgtt
  bpr-NF1           T[ggatcc]{.ul}atttcctgattcaccgaataa
  bpr-NR1           Cggaactccccattcccagtt
  bpr-CF1           Aactgggaatggggagttccgatcagaacaaggctatacag
  bpr-CR1           At[actagt]{.ul}ataaccgacgaaaggcttcaa
  mpr-NF1           T[ggatcc]{.ul}tgctgctgattcagttgaaa
  mpr-NR1           Ggctgtaaggtttgaatgttt
  mpr-CF1           Aaacattcaaaccttacagccctgaaacgtataagctgacct
  mpr-CR1           At[actagt]{.ul}gagatgtgatgggttactgat
  nprB-NF1          T[gctagc]{.ul}atcaaaccccttcatacatca
  nprB-NR1          Cagatgtcgagagtctcacaa
  nprB-CF1          Ttgtgagactctcgacatctgatgaaatcacacacgcagtca
  nprB-CR1          At[actagt]{.ul}atagaatgccgacagcctca
  vpr-NF1           T[ggatcc]{.ul}tctccgcaaatggatgacagt
  vpr-NR1           Ctgttgccgtttgaggtaac
  vpr-CF1           Gttacctcaaacggcaacagtgttatggatacgtggatgat
  vpr-CR1           At[actagt]{.ul}tacttttgcagtggctttccc
  wprA-NF1          T[ggatcc]{.ul}ggttgaaatgagtgtcgatca
  wprA-NR1          Ttatgtacggatgagaggct
  wprA-CF1          Agcctctcatccgtacataattgcagcccaaagcgataac
  wprA-CR1          At[actagt]{.ul}agcttaggattttgagcaaac

Underlined sequences are the restriction enzyme sites. Bolded sequences represent the 20 bp synthetic gRNA.

The 20 bp gRNA-containing oligonucleotides were generated by mixing synthetic primers x-gF1 and x-gR1 (× indicates the target genes; *aprE, nprE, epr, bpr, mpr, nprB, vpr*, and *wprA*). The oligonucleotides were ligated with AarI-digested pG2 to produce eight pG2 derivatives. For further cloning of donor DNAs, 500 bp fragments of each of the N- and C-terminus of the target site were amplified using the *B. subtilis* 168 chromosome as a template, with primer sets x-NF1/x-NR1 and x-CF1/x-CR1. The fusion PCR of the two DNA fragments, with primers x-NF1/x-CR1, resulted in a 1 kb donor DNA. Then the donor DNAs were digested with BamHI and SpeI and ligated with the corresponding the pG2 derivatives to convert pG2-aE to pG2-wA (NheI instead of BamHI in pG2-nB) ([Table 1](#T1){ref-type="table"}). To construct pG-aE, EcoRI- and HindIII-, digested pG2-aE was treated with dNTPs and the Klenow fragment, followed by blunt end ligation.

Serial Gene Editing in *B. subtilis*
------------------------------------

BS-C100, a *B. subtilis* 168 derivative carrying pHCas9 ([@B36]) was transformed with the sgRNAs-containing plasmids. The transformed cells were spread on LB agar plate supplemented with chloramphenicol (5 μg/ml) and neomycin (10 μg/ml). One colony selected from the plate was cultured in the 2×GYS -I medium containing neomycin (10 μg/ml) for 16 h. Subsequently, the cells were heat-treated at 80°C for 1 h and spread on the LB agar plate containing neomycin (10 μg/ml). The colonies on the plate were observed for antibiotic sensitivity to chloramphenicol (5 μg/ml) to select the colonies that have been removed from the sgRNAs-containing plasmid. The mutations were confirmed by the colony of PCR, DNA sequencing, and protease assay.

Protease Assay
--------------

Protease assay was performed using FTC (fluorescein isothiocyante)-casein as a substrate provided by the Pierce Fluorescent Protease Assay Kit (Thermo Scientific, Rockford, IL, United States). *Bacillus* cells were cultured in LB medium for 16 h at 37°C. Following this, the culture supernatants were collected by centrifugation at 10,000 × *g* for 5 min. The FTC-casein working reagent (100 μl) was mixed with 100 μl of the diluted supernatants (2^−8^) and incubated at room temperature for 24 h. The 10% trichloroacetic acid (400μl) was added to the mixture and incubated at ambient temperature for 5 min. After centrifugation at 10,000 × *g* for 5 min, 300 μl of the supernatant was mixed with 900 μl of 0.5 M Tris, pH 9, to measure fluorescence. Fluorescence intensity (excitation, 485 nm; emission, 535 nm) was measured using the TriStar^2^ LB 942 Multimode Reader (Berthold Technologies GmbH & Co. KG, Bad Wildbad, Germany). Blank fluorescence was subtracted from each measurement and the fluorescence reading was normalized to OD~600~ = 1.

Results
=======

Construction of the Self-Targeting sgRNA Module
-----------------------------------------------

Most of the CRISPR/Cas9-based genome editing in *B. subtilis* has been performed through plasmid-mediated methods ([@B1]; [@B43]; [@B7]; [@B36]). In multi-round genome editing, the elimination of sgRNA-containing plasmid is essential for the following round. It was reported that the CRISPR/Cas9 system using sgRNA~st~ was used as a tool for plasmid removal in *E. coli* ([@B19]). However, the transcription of the sgRNA~st~ needs to be tightly regulated because the unnecessary removal of sgRNA~st~-containing plasmid through leaky transcriptions may result in the simultaneous removal of sgRNA~ct~, which can hinder the genome editing.

In *B. subtilis*, the expression of sporulation-relating genes are tightly regulated by the phosphorylation of the master regulator Spo0A, and by the cascade activation of sporulation-specific sigma factors, σ^*F*^, σ^*E*^, σ^*G*^, and σ^*K*^ ([@B28]). Thus, a sporulation-specific promoter (P~spoIV\ A~) ([@B31]; [@B14]) was selected for the tight-control transcription of the sgRNA~st~. The sgRNA~st~ contains 20 bp gRNA sequence targeting replication origin of plasmid pAD123 ([Figure 1A](#F1){ref-type="fig"}). To confirm the self-curing system, the *B. subtilis* strain BS-C100 containing pHCas9 ([@B36]) was transformed with the plasmid pSC1 containing sgRNA~st~. The resulting strains of BS-D119a were cultured for 16 h in a sporulation medium (2×GYS) containing neomycin. Following the heat treatment, the cells were spread on the LB neomycin or chloramphenicol agar plate. We expected that the sgRNA~st~/Cas9 complex would attack its own replication origin during the sporulation phase to exhibit chloramphenicol sensitivity ([Figure 1B](#F1){ref-type="fig"}). All seventy colonies selected for antibiotic susceptibility tests showed sensitivity to chloramphenicol, indicating that the curing system works well with 100% efficiency ([Figure 1C](#F1){ref-type="fig"}).

![Development of plasmid curing system using Cas9 and self-targeting sgRNA (sgRNA~st~). **(A)** Sequence of a self-targeting sgRNA under the control of P~spoIV\ A~ promoter, 20 bp self-targeting gRNA (gRNA~st~), Cas9 binding scaffold, and transcriptional terminator. **(B)** Scheme of the plasmid self-curing. Introduction of plasmid pSC1 into strain BS-C100 and incubation in sporulation medium lead to the removal of pSC1; Ps and g1 indicate sporulation-specific promoter and gRNA~st~, respectively. **(C)** After self-curing, all *B. subtilis* colonies were grown on LB neomycin (LB neo) plates, but did not grow on LB chloramphenicol (LB cm) plates.](fmicb-10-01140-g001){#F1}

Growth-Phase Dependent Automatic sgRNAs-Exclusion System
--------------------------------------------------------

Using the curing system, we developed an efficient, multi-round genome editing process for *B. subtilis* ([Figure 2](#F2){ref-type="fig"}). The system contains two plasmids: One carries a *cas9* gene, and the other contains a donor DNA and two sgRNAs -- sgRNA~st~ and sgRNA~ct~. In the growth phase, Cas9 and sgRNA~ct~ are synthesized by the constitutive promoter and complexed to cleave the chromosomal target. The target editing occurs through a homologous recombination between the target and the donor DNA. In the sporulation phase, the sgRNA~st~ is synthesized and complexed with the Cas9 to cleave the sgRNAs-bearing plasmid. The resulting sgRNA-free cells are ready for the next round of editing.

![Strategy for serial genome editing in *B. subtilis*. The pG2 plasmid containing sgRNA~ct~, sgRNA~st~, and donor DNA fragment is introduced into pHCas9-containing cells. In the growth phase, sgRNA~ct~/Cas9 complex is responsible for target gene editing. In the sporulation phase, sgRNA~st~/Cas9 complex make double strand breaks in the replication origin (rep) of the pG2 for self-curing. Thus, the cells are ready for the next round of editing which can be transformed with the new pG2 plasmid.](fmicb-10-01140-g002){#F2}

To confirm the system, two plasmids -- pG-aE and pG2-aE -- were constructed ([Figure 3A](#F3){ref-type="fig"}). The pG-aE contains *aprE*-targeting sgRNA, under the control of constitutive a P~ara~ promoter ([@B36]) and the donor DNA, while the pG2-aE has the donor DNA and two sgRNAs---the *aprE*- and self-targeting sgRNAs. After introducing the two plasmids into the BS-C100, transformants were used to measure the efficiency of the *aprE* gene deletion and sgRNA-containing plasmid curing. Both plasmids showed similar *aprE* deletion efficiencies (80%), but different plasmid curing efficiencies. The curing efficiency of the plasmid pG-aE, which carries no sgRNA~st~, was less than 20%, while the efficiency of the plasmid pG2-aE, which contains both sgRNA~ct~ and sgRNA~st~, showed 74%. The curing efficiency of pG2-aE was reduced compared to the plasmid pSC1 containing only sgRNA~st~, which exhibited 100% efficiency. However, the efficiency was restored to 98% when the *cas9* expression was induced by the IPTG ([Figure 3B](#F3){ref-type="fig"}). The results showed that our system can induce both genomic target-editing and removal of sgRNA-containing plasmids, in a growth-phase dependent manner, and the curing efficiency can be increased by the overexpression of the *cas9* gene.

![Plasmid curing efficiency, according to the existence of the sgRNA~st~. **(A)** The construction of two plasmids pG-aE and pG2-aE for *aprE* gene deletion and self-curing. **(B)** The comparison of plasmid curing efficiency. The use of IPTG could increase the curing efficiency of pG2-aE from 74 to 98%. The bars display the means of three independent experiments, with the error bars indicating standard deviations.](fmicb-10-01140-g003){#F3}

Consecutive Deletion of Eight Extracellular Protease Genes
----------------------------------------------------------

*B. subtilis* has eight extracellular proteases known as: *aprE*, *nprE*, *epr*, *bpr*, *mpr*, *nprB*, *vpr*, and *wprA*. Extracellular protease deficient *B. subtilis* strains, such as WB800, were constructed to enhance the stability of the secreted heterologous proteins ([@B41]; [@B27]). The WB800 strain carries antibiotic resistance markers that confer resistances to bleomycin, blasticidin S, hygromycin, and chloramphenicol ([@B42]). The chloramphenicol resistance gene was disrupted due to the insertion of neomycin resistance genes in the *B. subtilis* WB800N strain ([@B18]). The construction of an eight, extracellular protease deficient mutant can be a good example for demonstrating our system. Eight plasmids (from pG2-aE to pG2-wA) were constructed to perform the consecutive deleting of the eight protease genes ([Table 1](#T1){ref-type="table"}). We sequentially introduced the eight plasmids into the BS-C100. Through the repetitive process of genome editing and plasmid self-curing, eight strains from BS-D119 to BS-D126 were obtained. Eight protease deficiencies of the final strain BS-D126 were confirmed by the PCR, using eight primer sets x-NF1/x-CR1 and DNA sequencing ([Figure 4A,B](#F4){ref-type="fig"}). The efficiencies of gene deletion and plasmid curing of each mutant strain did not change significantly ([Figure 4C](#F4){ref-type="fig"}). The protease assay showed that its extracellular activity was cumulatively decreased by the sequential removal of eight extracellular protease genes ([Figure 5](#F5){ref-type="fig"}).

![Deletion of eight extracellular protease genes in *B. subtilis*. **(A)** The chromosome structure of wild type strain (*B. subtilis* 168) and the deletion mutants of protease genes. The squared N and C indicate 500 bp donor DNA of each N- and C-terminus. The arrows indicate primer binding regions. **(B)** PCR analysis for confirming the deletion of each extracellular protease gene, using primer sets NF1/CR1. 1 indicates a wild type strain and 2 indicates strain BS-D126. Expected sizes of PCR products are 1.5 and 1.0 kb from wild type and mutant, respectively. **(C)** The mutation (gray) and curing (white) efficiencies of each mutant strain. The bars display the means of three independent experiments, with the error bars indicating standard deviations.](fmicb-10-01140-g004){#F4}

![The protease assay using FTC-Casein as substrate for confirming the serial deletion of extracellular protease genes. The protease activity of deletion mutants is compared to the wild type strain (*B. subtilis* 168) and the WB800N. The protease activity was assessed as changes in fluorescence through the digestion of the FTC-Casein substrate. The bars display the means of three independent experiments, with the error bars indicating standard deviations.](fmicb-10-01140-g005){#F5}

Discussion
==========

The genome editing of *B. subtilis* has been achieved by using antibiotic resistance markers for positive selection. However, *B subtilis* is a generally recognized as safe (GRAS) microorganism and has been used on many industrial applications requiring to be free of antibiotic resistance markers. Thus, the food-grade genome editing methods are needed for *B. subtilis*. Various counter-selectable markers such as *upp* ([@B12]), *blaI* ([@B5]), *mazF* ([@B44]), *araR* ([@B24]), and *hewI* ([@B39]) have been used to replace the antibiotic resistance markers in the genome editing of *B. subtilis*. However, the methods using *upp*, *blaI*, and *araR* require prior modifications on the second region of the chromosome and left traces of foreign DNA in the genome. The methods using toxic genes, such as *mazF* and *hewI* often generate undesired spontaneous resistant mutants. To overcome the limitation of the previous methods, a genome editing method using a synthetic gene circuit was developed ([@B16]). Since CRISPR/Cas9-mediated genome editing methods have been widely spread, they have also been applied in *B. subtilis*, recently ([@B15]).

CRISPR/Cas9-mediated genome editing in *B. subtilis* has been carried out through chromosomal expression ([@B40]) or plasmid-based methods ([@B1]; [@B43]; [@B36]). The chromosomal expression method enabled site-specific mutation, gene insertion, continuous genome editing, multiplexing and CRISPR interference ([@B40]). However, consecutive genome editing using the chromosomal integration system requires repeated restoration of the native *thrC* locus, which is the gRNA integration site. Furthermore, using toxic genes, such as *mazF* to restore the native *thrC* gene locus may result in undesirable spontaneous resistance mutations. An all-in-one system in which the *cas9*, gRNA, and donor DNA are assembled in a single plasmid was successfully used to delete the 25.1 and 4.1 kb DNA fragments from the genome and repair the *trpC2* mutation of *B. subtilis* 168 ([@B1]). Another all-in-one system was used to multigene disruption in undomesticated *B. subtilis* ATCC 6051a ([@B43]). Although the single plasmid systems have been successfully used on the genome editing of *B. subtilis*, the large-sized plasmid may limit restriction enzyme sites for cloning and affect negatively to transformation and mutation efficiencies. We have also tried to use the all-in-one system. However, we obtained very poor mutation efficiency under our experimental condition. Thus, we modified the two-plasmid system previously reported for multi-round genome editing in *B. subtilis* ([@B36]).

All the plasmid-based approaches require the efficient replacement of the sgRNA-containing plasmid in multi gene editing. Plasmid curing has been commonly accomplished through serial subcultures in a non-selective medium and by screening for the loss of plasmid. The temperature sensitive origin could be introduced for an efficient exclusion of vectors; however, those methods are laborious and time-consuming. Otherwise, counter selection markers may be included in the plasmid backbone, but these tend to cause mutational escape and often require particular conditions for the medium and host ([@B30]). In this study, we introduced the sgRNA~st~ to remove the sgRNA-containing plasmid. To avoid the sgRNA-containing plasmid removal, prior genome editing, the sgRNA~ct~ should be generated before the sgRNA~st~. We accomplished the condition by using the *spoIVA* promoter, which is completely repressed in the growth phase, to synthesize the sgRNA~st~, while the sgRNA~ct~ was synthesized under the control of the constitutive promoter. Thus, the temporal separation of the two sgRNA syntheses during cultivation enabled the genomic editing and sgRNA-containing plasmid removal to take place in sequence, which automatically made the cells ready for the next round in multiple genome editing. Our efficient gRNA removal system can largely simplify the multi-round genome editing process in comparison with the traditional negative selection methods for plasmid curing. Since the *spoIVA* promoter is a σ^*E*^-dependent, our system is limited when the gene required for the activation of σ^*E*^ is the deleting target, such as *spo0A* and *sigF*. In that case, the stationary phase-specific promoter ([@B22]), the acetoin-regulated promoter ([@B35]) or phosphate starvation-inducible promoter ([@B29]; [@B8]) may be used for the synthesis of the sgRNA~st~ instead of the *spoIVA* promoter.

The curing efficiency using the plasmid containing both sgRNA~ct~ and sgRNA~st~ was reduced to 74%, while the plasmid including only one sgRNA~st~ showed 100% curing efficiency ([Figure 3](#F3){ref-type="fig"}). We found that the curing efficiency using the plasmid containing both sgRNA~ct~ and sgRNA~st~ was restored to 98% when the expression of the *cas9* gene was induced by the IPTG. Thus, the reduction of the curing efficiency when using two sgRNAs may be due to insufficient amounts of Cas9 protein to produce sufficient sgRNA~st~/Cas9 complex at the sporulation phase, than when one sgRNA~st~ is used. A previous report showed that the leaky expression of the Cas9 without IPTG induction was enough to make an efficient mutation of the *B. subtilis* genome ([@B36]), suggesting that IPTG induction does not significantly change the mutation efficiency. The replication origin of the gRNA-containing plasmid was derived from the plasmid pTA1060 with a copy number of about 5 in *B. subtilis* ([@B6]). Our results suggest that the amount of Cas9 expressed by IPTG induction is sufficient to eliminate the 5-copy plasmid.

The self-curing system that we have developed here did not have the prerequisites, such as further gene sets and a host background. Although several inducible promoters have been reported for use in the *Bacillus* species ([@B4]; [@B26]), they showed basal expression levels even without inducers. If the inducible promoters exhibiting leaky expressions are used, the sequential occurrence of genome editing, and plasmid self-curing may be difficult. The difficult tight-control of inducible promoters in the *Bacillus* species suggests that a sporulation-phase specific promoter is useful for the controlled expression of the sgRNA~st~. Although our system is proven through consecutive gene deletion, we believe that it is capable of performing all sorts of multiple genome editing, including point mutations and insertions. This system may be applied to other *Bacillus* strain engineering and would be helpful in academic research, industrial production, therapeutics, and agricultural applications. Also, other microorganisms other than *Bacillus* can easily perform multiple genome editing, if an appropriate stationary phase specific promoter is used for the sgRNA~st~ synthesis.
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